Abbott Laboratories
ABT
$105.90
-$0.02-0.02%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 40.11B | 39.96B | 40.23B | 41.51B | 43.65B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 40.11B | 39.96B | 40.23B | 41.51B | 43.65B |
| Cost of Revenue | 17.93B | 17.94B | 17.96B | 18.41B | 19.08B |
| Gross Profit | 22.18B | 22.02B | 22.27B | 23.10B | 24.57B |
| SG&A Expenses | 10.41B | 10.57B | 10.60B | 10.63B | 10.70B |
| Depreciation & Amortization | 1.97B | 1.98B | 1.98B | 1.99B | 2.01B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.94B | 33.10B | 33.27B | 33.73B | 34.54B |
| Operating Income | 7.17B | 6.86B | 6.96B | 7.78B | 9.11B |
| Income Before Tax | 6.66B | 6.19B | 6.28B | 6.99B | 8.31B |
| Income Tax Expenses | 941.00M | 1.03B | 1.12B | 1.19B | 1.37B |
| Earnings from Continuing Operations | 5.72K | 5.16K | 5.16K | 5.80K | 6.93K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.72B | 5.16B | 5.16B | 5.80B | 6.93B |
| EBIT | 7.17B | 6.86B | 6.96B | 7.78B | 9.11B |
| EBITDA | 10.41B | 10.10B | 10.19B | 11.03B | 12.38B |
| EPS Basic | 3.27 | 2.95 | 2.94 | 3.30 | 3.93 |
| Normalized Basic EPS | 2.46 | 2.38 | 2.40 | 2.65 | 3.09 |
| EPS Diluted | 3.26 | 2.94 | 2.93 | 3.29 | 3.91 |
| Normalized Diluted EPS | 2.45 | 2.37 | 2.39 | 2.64 | 3.08 |
| Average Basic Shares Outstanding | 6.97B | 6.97B | 6.99B | 7.00B | 7.02B |
| Average Diluted Shares Outstanding | 7.00B | 7.00B | 7.02B | 7.03B | 7.06B |
| Dividend Per Share | 2.08 | 2.04 | 2.00 | 1.96 | 1.92 |
| Payout Ratio | 62.14% | 67.63% | 66.44% | 58.01% | 47.73% |
